Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D00MDP
|
||||
| Former ID |
DCL000004
|
||||
| Drug Name |
Prinomastat
|
||||
| Synonyms |
Opc 51803; AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide
|
||||
| Drug Type |
Small molecular drug
|
||||
| Therapeutic Class |
Anticancer Agents
|
||||
| Company |
Pfizer
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C18H21N3O5S2
|
||||
| InChI |
InChI=1S/C18H21N3O5S2/c1-18(2)16(17(22)20-23)21(11-12-27-18)28(24,25)15-5-3-13(4-6-15)26-14-7-9-19-10-8-14/h3-10,16,23H,11-12H2,1-2H3,(H,20,22)/t16-/m0/s1
|
||||
| InChIKey |
YKPYIPVDTNNYCN-INIZCTEOSA-N
|
||||
| CAS Number |
CAS 58-38-8
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| ChEBI ID |
ChEBI:8435
|
||||
| SuperDrug ATC ID |
N05AB04
|
||||
| SuperDrug CAS ID |
cas=000058388
|
||||
| Target and Pathway | |||||
| Pathway Interaction Database | LPA receptor mediated events | ||||
| Plasma membrane estrogen receptor signaling | |||||
| Osteopontin-mediated events | |||||
| Validated transcriptional targets of AP1 family members Fra1 and Fra2 | |||||
| Angiopoietin receptor Tie2-mediated signaling | |||||
| Direct p53 effectors | |||||
| amb2 Integrin signaling | |||||
| ATF-2 transcription factor network | |||||
| FOXM1 transcription factor network | |||||
| Regulation of nuclear beta catenin signaling and target gene transcription | |||||
| Syndecan-2-mediated signaling eventsendothelinpathway:Endothelins | |||||
| Glucocorticoid receptor regulatory network | |||||
| AP-1 transcription factor network | |||||
| Syndecan-1-mediated signaling eventsajdiss_2pathway:Posttranslational regulation of adherens junction stability and dissassembly | |||||
| p75(NTR)-mediated signaling | |||||
| Syndecan-1-mediated signaling events | |||||
| Reactome | Collagen degradation | ||||
| Degradation of the extracellular matrix | |||||
| Activation of Matrix Metalloproteinases | |||||
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | |||||
| EPH-ephrin mediated repulsion of cellsR-HSA-1442490:Collagen degradation | |||||
| Basigin interactions | |||||
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)R-HSA-1442490:Collagen degradation | |||||
| Assembly of collagen fibrils and other multimeric structures | |||||
| WikiPathways | Activation of Matrix Metalloproteinases | ||||
| AGE/RAGE pathway | |||||
| Matrix MetalloproteinasesWP366:TGF beta Signaling Pathway | |||||
| Bladder Cancer | |||||
| Degradation of collagen | |||||
| Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis | |||||
| Oncostatin M Signaling Pathway | |||||
| Prostate Cancer | |||||
| Integrated Breast Cancer Pathway | |||||
| Integrated Cancer pathway | |||||
| Cell surface interactions at the vascular wall | |||||
| Matrix MetalloproteinasesWP399:Wnt Signaling Pathway and Pluripotency | |||||
| Matrix Metalloproteinases | |||||
| References | |||||
| Ref 536056 | Emerging therapies for neuropathic pain. Expert Opin Emerg Drugs. 2005 Feb;10(1):95-108. | ||||
| Ref 541642 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6505). | ||||
| Ref 528049 | Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer. 2006 Mar;6(3):227-39. | ||||
| Ref 536127 | AG-3340 (Agouron Pharmaceuticals Inc). IDrugs. 2000 Mar;3(3):336-45. | ||||
| Ref 536723 | Pharmacoproteomics of a metalloproteinase hydroxamate inhibitor in breast cancer cells: dynamics of membrane type 1 matrix metalloproteinase-mediated membrane protein shedding. Mol Cell Biol. 2008 Aug;28(15):4896-914. Epub 2008 May 27. | ||||
| Ref 536808 | Delayed administration of a matrix metalloproteinase inhibitor limits progressive brain injury after hypoxia-ischemia in the neonatal rat. J Neuroinflammation. 2008 Aug 11;5:34. | ||||
| Ref 537136 | Inhibition of gelatinase activity reduces neural injury in an ex vivo model of hypoxia-ischemia. Neuroscience. 2009 Jun 2;160(4):755-66. Epub 2009 Mar 9. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.